Psyence Biomedical
About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Employees: 10
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
663% more capital invested
Capital invested by funds: $201K [Q3] → $1.53M (+$1.33M) [Q4]
76.16% more ownership
Funds ownership: 12.06% [Q3] → 88.22% (+76.16%) [Q4]
8% less funds holding
Funds holding: 12 [Q3] → 11 (-1) [Q4]
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for PBM.
Financial journalist opinion
Based on 5 articles about PBM published over the past 30 days
Neutral
Newsfile Corp
1 week ago
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Rule").
Neutral
GlobeNewsWire
1 week ago
Psyence Group Announces Share Consolidation
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share capital (the "Common Shares") on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the "Share Consolidation"), effective April 23, 2025 with a record date of April 23, 2025 (the "Record Date").
Neutral
Newsfile Corp
1 week ago
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.
Neutral
Newsfile Corp
2 weeks ago
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
New partnership strengthens Psyence BioMed's global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder New York, New York--(Newsfile Corp. - April 8, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the signing of a Letter of Intent (LOI) with Southern Star Research Pty Ltd, a premier Australian contract research organization (CRO). This collaboration will accelerate Psyence BioMed's ongoing Phase IIb psilocybin clinical trial in Australia, which focuses on adjustment disorder in patients diagnosed with cancer.
Neutral
Newsfile Corp
3 weeks ago
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025 New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") releases the following update: Dear Shareholders and Future Investors: At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders.
Neutral
Newsfile Corp
1 month ago
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J.
Neutral
GlobeNewsWire
1 month ago
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D.
Neutral
GlobeNewsWire
2 months ago
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.
Neutral
GlobeNewsWire
3 months ago
Psyence Biomed Announces Closing of $2.0 Million Private Placement
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A common warrants expire five years from the date of issuance and the short-term series B common warrants expire two years from the date of issuance.
Neutral
GlobeNewsWire
4 months ago
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Charts implemented using Lightweight Charts™